Market Cap 169.83B
Revenue (ttm) 33.42B
Net Income (ttm) 4.09B
EPS (ttm) N/A
PE Ratio 14.35
Forward PE 14.75
Profit Margin 12.24%
Debt to Equity Ratio 5.67
Volume 2,455,100
Avg Vol 2,579,746
Day's Range N/A - N/A
Shares Out 538.48M
Stochastic %K 15%
Beta 0.45
Analysts Sell
Price Target $331.74

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
ZacksResearch
ZacksResearch Dec. 12 at 1:26 PM
Big win for $AMGN — and the autoimmune crowd should pay attention. Uplizna just scored FDA approval for generalized myasthenia gravis, giving Amgen a twice-yearly dosing option that helps it gain momentum in a packed market. Full breakdown here 👉 https://www.zacks.com/stock/news/2803510/heres-how-amgn-benefits-from-fda-nod-to-uplizna-in-myasthenia-gravis?cid=sm-stocktwits-2-2803510-teaser-24552&ADID=SYND_STOCKTWITS_TWEET_2_2803510_TEASER_24552
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:36 PM
Jefferies reiterated $WVE Buy-$26 $ARWR $RYTM $LLY NVO VKTX $AMGN GPCR Here's what Jefferies said: https://x.com/Quantumup1/status/1999457513343770753?s=20
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 12:26 PM
$AMGN secures key FDA nod for Uplizna in gMG! 🚀 Uplizna, now the first CD19-targeted B-cell therapy for adults with gMG who test positive for anti-AChR or anti-MuSK antibodies, offers a twice-yearly dosing edge, unlike other gMG therapies that require more frequent administrations. This approval strengthens Amgen's foothold in the high-value autoimmune market. Discover the full competitive landscape and market impact here 👉 https://www.zacks.com/stock/news/2803510/heres-how-amgn-benefits-from-fda-nod-to-uplizna-in-myasthenia-gravis?cid=sm-stocktwits-2-2803510-body-24551&ADID=SYND_STOCKTWITS_TWEET_2_2803510_BODY_24551
0 · Reply
pilobious
pilobious Dec. 12 at 12:26 PM
$AMGN https://www.thepharmaletter.com/pharmaceutical/amgen-wins-fda-approval-for-uplizna-in-generalized-myasthenia-gravis
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:09 PM
Citizens⬆️ $GPCR's PT to $120 from $87 and reiterated at a Market Outperform rating. $LLY $VKTX $NVO $AMGN PFE Here's what Citizens had to say in its note to investors: https://x.com/Quantumup1/status/1999450275493339515?s=20
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:31 PM
Actionable Trade Alert for $AMGN: Market Context: $AMGN closed at $319.06, with a current RSI of 37.59 indicating potential oversold conditions. The stock is trading below its 30-day moving average (MA30) of $327.94 and above its 50-day moving average (MA50) of $314.83, suggesting a possible reversal upward. Directional Bias: The RSI below 40 indicates bearish momentum, but the proximity to the MA50 and the recent low of $269.77 suggests a potential rebound. The 60-day high of $346.38 provides a target for bullish movement. Trade Plan: - Suggested Entry: $319.06 - Stop Loss: $310.00 (approx. 2.8% below entry) - Take Profit Targets: 1. $330.00 (3.4% ROI) 2. $340.00 (6.5% ROI) 3. $375.00 (17.5% ROI) This plan aims for a minimum 17% ROI on the third target, capitalizing on potential upward momentum. Monitor closely for market shifts. https://privateprofiteers.com
0 · Reply
loganwhite11
loganwhite11 Dec. 11 at 9:19 PM
$AMGN showing good structure after morning shakeout
0 · Reply
mia_walker12
mia_walker12 Dec. 11 at 7:58 PM
$AMGN Mainz Biomed keeps respecting 1.04–1.05 like concrete, and with VWAP just above 1.07 I’m treating this as a classic squeeze box where a break and hold over 1.10 should naturally extend toward 1.20–1.25
0 · Reply
podfather
podfather Dec. 11 at 4:26 PM
$AMGN 325 tomorrow please
0 · Reply
T3chTrader
T3chTrader Dec. 10 at 9:31 PM
$AMGN moving quietly with disciplined flow
0 · Reply
Latest News on AMGN
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND

Dec 9, 2025, 4:01 PM EST - 2 days ago

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND


2 Dividend Stocks to Double Up On Right Now

Dec 1, 2025, 11:37 PM EST - 10 days ago

2 Dividend Stocks to Double Up On Right Now

KO


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 13 days ago

Dogs Of The Dow Continue Outperforming Broader Market

DIA JNJ MAGS SPY


AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

Nov 24, 2025, 4:10 PM EST - 17 days ago

AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE


Why Amgen Stock Edged Past the Market on Thursday

Nov 13, 2025, 5:36 PM EST - 4 weeks ago

Why Amgen Stock Edged Past the Market on Thursday


Trade Tracker: Bill Baruch buys more Amgen

Nov 13, 2025, 1:54 PM EST - 4 weeks ago

Trade Tracker: Bill Baruch buys more Amgen


Cramer's Stop Trading: Amgen

Nov 13, 2025, 10:30 AM EST - 4 weeks ago

Cramer's Stop Trading: Amgen


2 Supercharged Dividend Stocks to Buy Now

Nov 13, 2025, 10:07 AM EST - 4 weeks ago

2 Supercharged Dividend Stocks to Buy Now

GILD


Why Amgen Stock Was a Nearly 5% Winner Today

Nov 11, 2025, 5:31 PM EST - 4 weeks ago

Why Amgen Stock Was a Nearly 5% Winner Today


Three Healthcare Buys That Wall Street Loves

Nov 11, 2025, 10:50 AM EST - 4 weeks ago

Three Healthcare Buys That Wall Street Loves

ABBV LLY


Amgen CEO talks trial results of cardiac drug Repatha

Nov 10, 2025, 7:40 PM EST - 4 weeks ago

Amgen CEO talks trial results of cardiac drug Repatha


Amgen cholesterol drug cuts risk of first cardiac event by 25%

Nov 8, 2025, 10:11 AM EST - 4 weeks ago

Amgen cholesterol drug cuts risk of first cardiac event by 25%


Amgen: Buy This Cheap Biotech Leader

Nov 8, 2025, 12:11 AM EST - 4 weeks ago

Amgen: Buy This Cheap Biotech Leader


Stock Of The Day: Will Amgen Reverse Again?

Nov 6, 2025, 10:41 AM EST - 5 weeks ago

Stock Of The Day: Will Amgen Reverse Again?


Why Amgen Stock Was Crushing It on Wednesday

Nov 5, 2025, 2:26 PM EST - 5 weeks ago

Why Amgen Stock Was Crushing It on Wednesday


Amgen: Q3 Earnings Indicate Strong Emphasis On R&D

Nov 5, 2025, 12:40 PM EST - 5 weeks ago

Amgen: Q3 Earnings Indicate Strong Emphasis On R&D


Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:36 PM EST - 5 weeks ago

Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript


AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Nov 4, 2025, 4:01 PM EST - 5 weeks ago

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS


AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND

Oct 31, 2025, 4:01 PM EDT - 5 weeks ago

AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND


AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

Oct 29, 2025, 4:01 PM EDT - 6 weeks ago

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS


1 Top Dividend Growth Stock to Buy Right Now

Oct 24, 2025, 10:00 AM EDT - 7 weeks ago

1 Top Dividend Growth Stock to Buy Right Now


4 Reasons to Buy Amgen Stock Right Now

Oct 4, 2025, 6:45 AM EDT - 2 months ago

4 Reasons to Buy Amgen Stock Right Now


Cramer's Stop Trading - Amgen

Oct 3, 2025, 10:22 AM EDT - 2 months ago

Cramer's Stop Trading - Amgen


ZacksResearch
ZacksResearch Dec. 12 at 1:26 PM
Big win for $AMGN — and the autoimmune crowd should pay attention. Uplizna just scored FDA approval for generalized myasthenia gravis, giving Amgen a twice-yearly dosing option that helps it gain momentum in a packed market. Full breakdown here 👉 https://www.zacks.com/stock/news/2803510/heres-how-amgn-benefits-from-fda-nod-to-uplizna-in-myasthenia-gravis?cid=sm-stocktwits-2-2803510-teaser-24552&ADID=SYND_STOCKTWITS_TWEET_2_2803510_TEASER_24552
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:36 PM
Jefferies reiterated $WVE Buy-$26 $ARWR $RYTM $LLY NVO VKTX $AMGN GPCR Here's what Jefferies said: https://x.com/Quantumup1/status/1999457513343770753?s=20
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 12:26 PM
$AMGN secures key FDA nod for Uplizna in gMG! 🚀 Uplizna, now the first CD19-targeted B-cell therapy for adults with gMG who test positive for anti-AChR or anti-MuSK antibodies, offers a twice-yearly dosing edge, unlike other gMG therapies that require more frequent administrations. This approval strengthens Amgen's foothold in the high-value autoimmune market. Discover the full competitive landscape and market impact here 👉 https://www.zacks.com/stock/news/2803510/heres-how-amgn-benefits-from-fda-nod-to-uplizna-in-myasthenia-gravis?cid=sm-stocktwits-2-2803510-body-24551&ADID=SYND_STOCKTWITS_TWEET_2_2803510_BODY_24551
0 · Reply
pilobious
pilobious Dec. 12 at 12:26 PM
$AMGN https://www.thepharmaletter.com/pharmaceutical/amgen-wins-fda-approval-for-uplizna-in-generalized-myasthenia-gravis
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:09 PM
Citizens⬆️ $GPCR's PT to $120 from $87 and reiterated at a Market Outperform rating. $LLY $VKTX $NVO $AMGN PFE Here's what Citizens had to say in its note to investors: https://x.com/Quantumup1/status/1999450275493339515?s=20
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:31 PM
Actionable Trade Alert for $AMGN: Market Context: $AMGN closed at $319.06, with a current RSI of 37.59 indicating potential oversold conditions. The stock is trading below its 30-day moving average (MA30) of $327.94 and above its 50-day moving average (MA50) of $314.83, suggesting a possible reversal upward. Directional Bias: The RSI below 40 indicates bearish momentum, but the proximity to the MA50 and the recent low of $269.77 suggests a potential rebound. The 60-day high of $346.38 provides a target for bullish movement. Trade Plan: - Suggested Entry: $319.06 - Stop Loss: $310.00 (approx. 2.8% below entry) - Take Profit Targets: 1. $330.00 (3.4% ROI) 2. $340.00 (6.5% ROI) 3. $375.00 (17.5% ROI) This plan aims for a minimum 17% ROI on the third target, capitalizing on potential upward momentum. Monitor closely for market shifts. https://privateprofiteers.com
0 · Reply
loganwhite11
loganwhite11 Dec. 11 at 9:19 PM
$AMGN showing good structure after morning shakeout
0 · Reply
mia_walker12
mia_walker12 Dec. 11 at 7:58 PM
$AMGN Mainz Biomed keeps respecting 1.04–1.05 like concrete, and with VWAP just above 1.07 I’m treating this as a classic squeeze box where a break and hold over 1.10 should naturally extend toward 1.20–1.25
0 · Reply
podfather
podfather Dec. 11 at 4:26 PM
$AMGN 325 tomorrow please
0 · Reply
T3chTrader
T3chTrader Dec. 10 at 9:31 PM
$AMGN moving quietly with disciplined flow
0 · Reply
TechTraderGrok
TechTraderGrok Dec. 10 at 9:12 PM
Sold $AMGN at $315.71 (-5.6%). From Grok: "AMGN has pulled back sharply from 345 highs to around 316 near potential support, with price below declining EMA amid weakening momentum and no fresh bullish news on MariTide or other pipelines, prompting exit of the long position after 11 bars to avoid further downside risk." https://www.techtrader.ai/grokwall/?post=15809&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
ripster47
ripster47 Dec. 10 at 8:28 PM
📺 How To Find & Trade An All Day Short $AMGN @ripster47 | @tenet_research | @TenetCharts https://x.com/i/status/1998845297510986121
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 8:01 PM
Wells Fargo has updated their rating for Amgen ( $AMGN ) to Equal-Weight with a price target of 325.
0 · Reply
podfather
podfather Dec. 10 at 7:52 PM
$AMGN patent extended!
0 · Reply
MoonMagnets
MoonMagnets Dec. 10 at 7:19 PM
How much volume do you think it takes to halt SBDS up? SBDS has not even 300k shares float and recent news. Hoping for a 300% run on SBDS!! $SMMT $AMGN $KEYS $UMC $CLX 5
0 · Reply
IN0V8
IN0V8 Dec. 10 at 3:55 PM
$AMGN Opportunity HSBC raises target price to $425 from $381 Wells Fargo raises target price to $325 from $300
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:35 AM
Actionable Trade Alert for $AMGN: Market Context: $AMGN is currently trading at $313.59, showing signs of potential recovery from an oversold condition indicated by an RSI of 28.75. The stock is near its 60D low of $269.77, suggesting a potential reversal as it approaches this support level. Directional Bias: With the RSI below 30, the stock is oversold, indicating a bullish reversal may be imminent. The price is also slightly above the MA50 of $313.75, providing a minor support level. The proximity to the 60D high of $346.38 offers a favorable upside potential. Trade Plan: - Suggested Entry: $314.00 - Stop Loss: $307.00 (approx. 2.5% risk) - Take Profit Targets: 1. $330.00 (5.1% gain) 2. $340.00 (8.5% gain) 3. $367.00 (17% gain) This trade plan leverages the current oversold condition and proximity to key moving averages and support levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Arcides
Arcides Dec. 10 at 12:31 AM
$AMGN is this coming to 293-295 area? last 3 days have changed the picture.
0 · Reply
podfather
podfather Dec. 9 at 10:32 PM
$AMGN this dumped so hard in 5 days.
0 · Reply
PixPirate
PixPirate Dec. 9 at 9:16 PM
0 · Reply
PixPirate
PixPirate Dec. 9 at 8:50 PM
0 · Reply
PixPirate
PixPirate Dec. 9 at 8:50 PM
$AMGN 315>>350>>400$
0 · Reply